

# ACT-A Council Vaccine Manufacturing WG Meeting

---

WTO Virtual Information Session

12<sup>th</sup> October 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis



## ACT-A Council VMWG Objectives

**Overarching:** *Support COVAX Taskforce by addressing political bottlenecks and barriers*

- Address **supply chains for raw materials and vaccines**
- Identify and address all barriers, including legal and political, to **utilize existing and new production capacities in LMIC**
- Facilitate identification of **under-utilized/idle capacity** for viral vector, mRNA and other Vx technologies
- Facilitate solutions for **tech transfer** of approved products
- Unlock **political barriers** for increased manufacturing at the regional level
- Increase **information availability on Vx production and deliveries**
- Increase **transparency on the affordability of vaccines**, encourage Vx supplied to COVAX AMC are priced at the cost of goods and production
- Increase **political dialogue** and build global political consensus

## ACT-A Council VMWG Members



### **South Africa**

**Co-chair:** Zane Dangor

Special Advisor to the Minister of International Relations and Development



### **Germany**

**Co-chair:** Lars Hendrik Röllner

Director General for Economic and Financial Policy, German Chancellery



### **Norway**

John Arne Røttingen

Global Health Ambassador, Ministry of Foreign Affairs



### **Indonesia**

Dante Saksono Herbuwono

Vice Minister of Health, MoH



### **Brazil**

João Lucas de Almeida

Director of the Department of Human Rights and Citizenship,

MFA

### **India**

M. K. Aggarwal

Additional Commissioner, UIP, MoH&FW



### **South Korea**

Lee Kangho

Deputy Minister, Office of Pan-government Global Vaccine Hub



### **USA**

Timothy Manning

National COVID19 Supply Coordinator, White House



### **China**

Junfeng Mao

Deputy Director General, Department of Industry, Ministry of Industry and Information Technology



### **Saudi Arabia**

Abdullah Assiri

Assistant Deputy Minister, Preventive Health, MoH



### **Rwanda**

Theophile Dushime

Special Advisor to Minister, MoH

## ACT-A Council VMWG in G20 and G7 communique

### G20 Rome Declaration



“ *We affirm our support for efforts to strengthen supply chains and boost and diversify global vaccine manufacturing capacity*

“ ***We ask the Working Group and Task Force to report on their progress to the G20 in time for the Leaders’ Summit in October.** This report will be informed by the WHO and other international stakeholders and organisations, consistent with their mandates and decision-making rules, on how to improve equitable access in the current crisis.*

### G7 communique



“ ***... we will support the ACT-A Facilitation Council Working Group** together with the World Health Organisation (WHO), the World Trade Organisation (WTO), Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, UNICEF and other partners such as the Medicines Patent Pool and the private sector, to coordinate a global vaccine supply network to optimise manufacturing capacities ...*

## Workplan Overview | WG workstreams & core-areas of work\*

1

### Improve supply




-  Request suppliers & manufacturers engage in marketplace
-  Support WTO/WCO – expedition of customs\*
-  Facilitate agreements – easing of import/ export restrictions\*
-  Unblock general supply issues e.g. hoarding, backstopping measures



*Immediate/ short-term*

2

### Increase manufacturing capacity




-  Advocate to postpone shift to single dose vials in acute phase
-  Create manuf. awareness & outreach to CEPI for F&F / underutilized capacity
-  Lift travel restrictions for critical vaccine production workers



*Mid-term*

3

### Sustainable capacity in LMICs


-  Encourage producers to participate in tech transfer hub network
-  Support integration of parallel initiatives in expanding production\*
-  Support in-country needs & programs



*Longer term*

\* reflecting issues related to WTO

# Issues related to WTO in VMWG Workplan | Mainly in WS1



Refer to document for further details.  
Summarized version provided above.

# G20 Report | Outline

- **Executive summary and Recommendations**
- **Background**
- **ACT – A Council VMWG – mandate, way of working and processes**
- **Key Deliverables – COVAX MFTF and VMWG**
  - Improve input supply availability - short-term action
  - Maximize medium-term manufacturing capacity
  - New and expanded sustainable capacity in LMICs – long-term action
- **Recommendations to G20**
- **Annex**



ACT Accelerator Facilitation Council  
Vaccine Manufacturing Working Group –  
Report to the G20

DRAFT

Content

Index of Abbreviations	4
1 Executive Summary and Recommendations	4
2 Background	4
3 ACT Accelerator Facilitation Council Vaccine Manufacturing Working Group	10
4 Key Deliverables – COVAX MFTF and Vaccine Manufacturing Working Group	10
5.1 Workstream 1: Improve supply inputs to vaccine manufacturing and increase supply of vaccines to COVAX	14
5.1.1 Area of work: Create awareness within local manufacturer and supplier communities to join the COVAX input supply marketplace	14
5.1.2 Area of work: Advocate for participation in WHO and WFP governance and Monitor Status meetings to introduce and revise actions that could significantly accelerate expediting systems processes	15
5.1.3 Area of work: Facilitate rapid creation of needed bilateral and multilateral agreements to ease import export of needed input supplies	16
5.2 Workstream 2: Increase Manufacturing Capacity	16
5.2.1 Area of work: Persuade G20 to angle donor state until the acceleration of the pandemic is over	16
5.2.2 Area of work: Create awareness and advocate for local vaccine manufacturer communities to sign out to COVAX with their VBI capacity needs and underutilized capacity	18
5.2.3 Area of work: Lift any travel restrictions for critical personnel and address their COVID-19 vaccine requirements to support accordingly	18
5.2.4 Area of work: Recreate clinical trial stages of vaccine development	19
5.3 Workstream 3: New and expanded sustainable capacity in LMICs	19
5.3.1 Area of work: Encourage approved tech leaders to participate with their technology in the fully independent research	19
5.3.2 Area of work: Support to integrate parallel initiatives that could benefit from the effort	21
5.3.3 Area of work: Support to ensure programs and financing needs	21
6 Recommendations to the G20	26
7 Annex	28